Investing.com -- British American Tobacco (LON:BATS) (NYSE:BTI) reaffirmed its full-year guidance on Thursday after delivering better-than-expected first-half (1H25) results, pushing its shares more than 1% higher in London trading. The company said it remains on track to reach the upper end of its 2025 revenue growth target of 1% to 2% at constant exchange rates and anticipates a 1.5% to 2.5% rise in adjusted profit from operations. In the first half, adjusted operating profit came in at £5.39 billion, slightly ahead of last year’s £5.33 billion and above the company-compiled consensus of £5.21 billion. Revenue slipped to £12.07 billion from £12.34 billion, though this too exceeded the £12 billion forecast. The company said its U.S. revenue, which accounts for roughly 44% of group sales, rose 3.7% at constant currency in the first half. Growth in its new category products was 3.9%, supported by strong performance from Velo, its nicotine pouch brand. The company noted that its smokeless portfolio—which includes Velo, Vuse Ultra premium vapour, and glo Hilo heated tobacco—now represents over 18% of total revenue. "We would expect a gently positive share price reaction today given the reassurance regarding the strong growth potential of Velo Plus and the robust U.S. combustibles topline growth in 1H25," Jefferies analysts said in a post-earnings note. "BAT is, in our view, at an early stage of a successful transition towards a Smoke Free Products-centric portfolio," they added. Analysts expect BAT to generate £25.43 billion in full-year revenue and £11.20 billion in adjusted operating profit, compared to £25.87 billion and £11.37 billion, respectively, in 2024. Revenue from BAT’s newer product categories—such as vapour, heated tobacco, and oral nicotine pouches—was steady at £1.65 billion in the first half. The company expects growth in these categories to pick up to the mid-single digits in the second half. British American Tobacco also boosted its share buyback plan for the full year to £1.1 billion. Related articles BAT affirms guidance after H1 beat on operating profit, revenue; shares climb These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia Risks Rising? Smart Money Dodged 46%+ Drawdowns on These High-Flying Names View Comments
BAT affirms guidance after H1 beat on operating profit, revenue; shares climb
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...